Rosuvastatin Reduces Plasma Small Dense LDL-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pharmacology & Pharmacy

• Publication date

  2012-01-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4236/PP.2012.31011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.

  2008cited by this paper
• Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis.

  2008cited by this paper
• Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

  2008cited by this paper
• The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.

  2007cited by this paper
• A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.

  2007cited by this paper
• Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method

  2004influential reference
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004influential reference
• Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.

  2004cited by this paper
• A novel and simple method for quantification of small, dense LDL Published, JLR Papers in Press, August 1, 2003. DOI 10.1194/jlr.D300007-JLR200

  2003influential reference
• Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.

  2003cited by this paper
• Atherogenic lipoproteins and diabetes mellitus.

  2002influential reference
• Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.

  2002cited by this paper
• Treatment of small dense LDL.

  2002cited by this paper
• High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia.

  1998cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Low-density lipoprotein cholesterol can be chemically measured: a new superior method.

  1998cited by this paper
• Low-density lipoprotein subclasses: mechanisms of formation and modulation

  1997cited by this paper
• Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men.

  1996cited by this paper
• Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.

  1994influential reference
• Metabolism of VLDL and LDL subclasses.

  1994cited by this paper
• LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.

  1992cited by this paper
• Abnormal Lipoprotein Composition in Normolipidemic Diabetic Patients

  1990cited by this paper
• Low-density lipoprotein subclass patterns and risk of myocardial infarction.

  1988influential reference
• Complete protein sequence and identification of structural domains of human apolipoprotein B

  1986cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.

  1984influential reference
• Identification of multiple subclasses of plasma low density lipoproteins in normal humans.

  1982cited by this paper

• The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study

  2017cites this paper
• Lipid-lowering efficacy of rosuvastatin.

  2017cites this paper
• The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size

  2017cites this paper
• The Association Between Small Dense Low Density Lipoprotein and Coronary Artery Disease in North Indian Patients

  2016cites this paper
• Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus

  2016cites this paper
• Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.

  2016influential citation
• Status of Small Dense LDL in Cardiovascular Disease Subjects Taking Drug Therapy.

  2015cites this paper
• Estimation of Small, Dense LDL Particles Using Equations Derived FromRoutine Lipid Parameters as Surrogate Markers

  2014cites this paper